Keith Loven is a Dermatology physician affiliated with Rivergate Dermatology Clinical Research Center. OpenAlex indexes 11 publications with 860 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
201 Bluebird Dr
Goodlettsville, TN 37072
Telephone
615-859-7546Registry record last updated 15 Jul 2010.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
45 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- LEO Pharma Inc.Program year202540 payments$18,118openpaymentsdata.cms.gov ↗
- Hoffmann-La Roche LimitedProgram year20254 payments
- UCB SAProgram year20257 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
26.1%Corticosteroid26.1%Clobetasol Propionate68%Betamethasone Dipropionate17%Betamethasone Diprop Augmented11%Hydrocortisone4%Part D≥267 patientsDermatology
18.2%Corticosteroid8.1%Triamcinolone Acetonide91%Halobetasol Propionate9%Part D<11 patientsAntivirals6.8%Imiquimod100%Part D≥113 patients+ 3 more classes in this area
Anti-infectives
17.3%Azole Antifungal4.7%Ketoconazole100%Part D≥59 patientsNitroimidazole Antimicrobial4.4%Metronidazole100%Part D≥60 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream
Dermatologic Surgery
2006 - Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: A multicenter, double-blind, randomized, parallel-group trial
Journal of the American Academy of Dermatology
2005 - Long-Term Clinical Outcomes Following Treatment of Actinic Keratosis with Imiquimod 5% Cream
Dermatologic Surgery
2005 - Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study.
PubMed
2005
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”